NICOLE A. PILCH, Pharm.D., M.S., BCPS, FAST, (firstname.lastname@example.org) is director of system quality at the Medical University of South Carolina (MUSC) in Charleston. She received her Pharm.D. from the University of Wisconsin-Madison and completed both a PGY-1 pharmacy practice residency and a PGY-2 critical care residency at MUSC. Dr. Pilch also completed a fellowship in transplantation clinical research and completed a Masters in clinical research from the University of Cincinnati. She has served as a roundtable discussion leader for immunology/transplant in the ASHP Section of Clinical Specialists and Scientists and other special interest groups. She is currently a senior associate editor for AJHP and is on the transplant Board of Pharmaceutical Specialties. She has served on the American Transplant Society Pharmacists Community of Practice executive board, several ACCP Practice and Research Network for Transplant committees as chair and vice chair. She has served as the residency program director for the PGY1 pharmacy practice and PGY2 solid organ transplant residencies at MUSC. She remained in the clinic and at the bedside taking care of adult and pediatric solid organ transplant recipients for over 10 years and still practices in the kidney transplant clinic. She has served as a primary investigator for several studies and published several articles surrounding immunosuppression practices, patient safety, and the role of the transplant pharmacist. More recently, Dr. Pilch assumed the role as the system quality assurance performance improvement (QAPI) director. She has a clear understanding of the impact of rules and regulations on the quality and safety of patient care as well as the balance that is needed to facilitate operations in a high reliable and just culture environment.
Being a part of the ASHP Section of Clinical Specialists and Scientists throughout my career has been inspiring. This group of thought leaders and experts in clinical practice and the study of improving pharmacotherapy for our patients have provided numerous guidelines, papers, best practices, and novel approaches to evolving patient populations. The unique skill set of this group is needed, now more than ever, to produce high value healthcare for our patients. The value proposition is challenging and is based on perspective. The Section of Clinical Specialists and Scientists is in a unique position to be at the table with the rest of the multidisciplinary healthcare leaders to further define value and measure it.
I am deeply humbled by the nomination to be the section chair of this extraordinary group. If elected, I look forward to working alongside this group of thought leaders that can help shape value in healthcare and ensure that the pharmacist is on the forefront. I am eager to see provider status be extended and pharmacists to be involved in every aspect of patient care to ensure that medications are used in their most safe and effective way to improve outcomes.